Login to Your Account

Xenoport's GERD Phase IIb Data Give Investors Heartburn

By Catherine Shaffer

Tuesday, March 22, 2011
Xenoport Inc.'s stock took a 6.2 percent hit Monday as it reported that its gastroesophageal reflux (GERD) candidate, arbaclofen placarbil, failed to show significant benefits over placebo in a Phase IIb trial. The Santa Clara, Calif.-based company will not pursue the drug any further in GERD, but plans to initiate a Phase III trial in spasticity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription